GSK plc
GSK plc (GSK) Stock Competitors & Peer Comparison
See (GSK) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GSK | $59.46 | -2.28% | 120.1B | 15.75 | $3.78 | +2.96% |
| LLY | $1,051.24 | +2.74% | 952.9B | 43.99 | $22.96 | +0.62% |
| AZN | $205.40 | -0.51% | 633.8B | 31.30 | $6.53 | +1.82% |
| JNJ | $246.04 | -0.35% | 584.4B | 22.01 | $11.02 | +2.10% |
| ABBV | $228.65 | +1.92% | 397.6B | 95.32 | $2.36 | +2.94% |
| NVS | $164.39 | +0.29% | 314.5B | 22.78 | $7.14 | +2.01% |
| MRK | $122.93 | +0.87% | 305.4B | 16.80 | $7.28 | +2.68% |
| NVO | $39.88 | -17.69% | 210.9B | 12.96 | $3.66 | +2.59% |
| AMGN | $376.22 | +0.19% | 202B | 26.34 | $14.23 | +2.58% |
| GILD | $149.78 | -0.89% | 187.8B | 18.58 | $8.15 | +2.09% |
Stock Comparison
GSK vs LLY Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, LLY has a market cap of 952.9B. Regarding current trading prices, GSK is priced at $59.46, while LLY trades at $1,051.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas LLY's P/E ratio is 43.99. In terms of profitability, GSK's ROE is +0.30%, compared to LLY's ROE of +0.98%. Regarding short-term risk, GSK is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check LLY's competition here
GSK vs AZN Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, AZN has a market cap of 633.8B. Regarding current trading prices, GSK is priced at $59.46, while AZN trades at $205.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas AZN's P/E ratio is 31.30. In terms of profitability, GSK's ROE is +0.30%, compared to AZN's ROE of +0.23%. Regarding short-term risk, GSK is less volatile compared to AZN. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check AZN's competition here
GSK vs JNJ Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, JNJ has a market cap of 584.4B. Regarding current trading prices, GSK is priced at $59.46, while JNJ trades at $246.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas JNJ's P/E ratio is 22.01. In terms of profitability, GSK's ROE is +0.30%, compared to JNJ's ROE of +0.34%. Regarding short-term risk, GSK is less volatile compared to JNJ. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check JNJ's competition here
GSK vs ABBV Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, ABBV has a market cap of 397.6B. Regarding current trading prices, GSK is priced at $59.46, while ABBV trades at $228.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas ABBV's P/E ratio is 95.32. In terms of profitability, GSK's ROE is +0.30%, compared to ABBV's ROE of -4.22%. Regarding short-term risk, GSK is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check ABBV's competition here
GSK vs NVS Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, NVS has a market cap of 314.5B. Regarding current trading prices, GSK is priced at $59.46, while NVS trades at $164.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas NVS's P/E ratio is 22.78. In terms of profitability, GSK's ROE is +0.30%, compared to NVS's ROE of +0.33%. Regarding short-term risk, GSK is less volatile compared to NVS. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check NVS's competition here
GSK vs MRK Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, MRK has a market cap of 305.4B. Regarding current trading prices, GSK is priced at $59.46, while MRK trades at $122.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas MRK's P/E ratio is 16.80. In terms of profitability, GSK's ROE is +0.30%, compared to MRK's ROE of +0.36%. Regarding short-term risk, GSK is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check MRK's competition here
GSK vs NVO Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, NVO has a market cap of 210.9B. Regarding current trading prices, GSK is priced at $59.46, while NVO trades at $39.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas NVO's P/E ratio is 12.96. In terms of profitability, GSK's ROE is +0.30%, compared to NVO's ROE of +0.61%. Regarding short-term risk, GSK is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check NVO's competition here
GSK vs AMGN Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, AMGN has a market cap of 202B. Regarding current trading prices, GSK is priced at $59.46, while AMGN trades at $376.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas AMGN's P/E ratio is 26.34. In terms of profitability, GSK's ROE is +0.30%, compared to AMGN's ROE of +0.97%. Regarding short-term risk, GSK is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check AMGN's competition here
GSK vs GILD Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, GILD has a market cap of 187.8B. Regarding current trading prices, GSK is priced at $59.46, while GILD trades at $149.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas GILD's P/E ratio is 18.58. In terms of profitability, GSK's ROE is +0.30%, compared to GILD's ROE of +0.41%. Regarding short-term risk, GSK is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check GILD's competition here
GSK vs PFE Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, PFE has a market cap of 151.6B. Regarding current trading prices, GSK is priced at $59.46, while PFE trades at $26.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas PFE's P/E ratio is 19.60. In terms of profitability, GSK's ROE is +0.30%, compared to PFE's ROE of +0.09%. Regarding short-term risk, GSK is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check PFE's competition here
GSK vs BMY Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, BMY has a market cap of 123.6B. Regarding current trading prices, GSK is priced at $59.46, while BMY trades at $61.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas BMY's P/E ratio is 17.54. In terms of profitability, GSK's ROE is +0.30%, compared to BMY's ROE of +0.39%. Regarding short-term risk, GSK is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check BMY's competition here
GSK vs SNY Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, SNY has a market cap of 113.6B. Regarding current trading prices, GSK is priced at $59.46, while SNY trades at $47.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas SNY's P/E ratio is 19.48. In terms of profitability, GSK's ROE is +0.30%, compared to SNY's ROE of +0.11%. Regarding short-term risk, GSK is less volatile compared to SNY. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check SNY's competition here
GSK vs BIIB Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, BIIB has a market cap of 28.2B. Regarding current trading prices, GSK is priced at $59.46, while BIIB trades at $195.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas BIIB's P/E ratio is 21.85. In terms of profitability, GSK's ROE is +0.30%, compared to BIIB's ROE of +0.07%. Regarding short-term risk, GSK is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check BIIB's competition here
GSK vs HZNP Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, GSK is priced at $59.46, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas HZNP's P/E ratio is 61.86. In terms of profitability, GSK's ROE is +0.30%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, GSK is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check HZNP's competition here
GSK vs GRFS Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, GRFS has a market cap of 8B. Regarding current trading prices, GSK is priced at $59.46, while GRFS trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas GRFS's P/E ratio is 14.46. In terms of profitability, GSK's ROE is +0.30%, compared to GRFS's ROE of +0.07%. Regarding short-term risk, GSK is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check GRFS's competition here
GSK vs OGN Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, OGN has a market cap of 2.1B. Regarding current trading prices, GSK is priced at $59.46, while OGN trades at $8.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas OGN's P/E ratio is 11.25. In terms of profitability, GSK's ROE is +0.30%, compared to OGN's ROE of +0.24%. Regarding short-term risk, GSK is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check OGN's competition here
GSK vs CELG-RI Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, CELG-RI has a market cap of 163.3M. Regarding current trading prices, GSK is priced at $59.46, while CELG-RI trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, GSK's ROE is +0.30%, compared to CELG-RI's ROE of +0.39%. Regarding short-term risk, GSK is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check CELG-RI's competition here
GSK vs CTOR Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, CTOR has a market cap of 102.4M. Regarding current trading prices, GSK is priced at $59.46, while CTOR trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas CTOR's P/E ratio is -3.74. In terms of profitability, GSK's ROE is +0.30%, compared to CTOR's ROE of -0.55%. Regarding short-term risk, GSK is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check CTOR's competition here
GSK vs SCLX Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, SCLX has a market cap of 69.4M. Regarding current trading prices, GSK is priced at $59.46, while SCLX trades at $8.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas SCLX's P/E ratio is -0.20. In terms of profitability, GSK's ROE is +0.30%, compared to SCLX's ROE of +1.81%. Regarding short-term risk, GSK is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check SCLX's competition here
GSK vs MIRA Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, MIRA has a market cap of 49.8M. Regarding current trading prices, GSK is priced at $59.46, while MIRA trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas MIRA's P/E ratio is -0.74. In terms of profitability, GSK's ROE is +0.30%, compared to MIRA's ROE of -9.79%. Regarding short-term risk, GSK is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check MIRA's competition here
GSK vs SRXH Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, SRXH has a market cap of 4.3M. Regarding current trading prices, GSK is priced at $59.46, while SRXH trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas SRXH's P/E ratio is -0.75. In terms of profitability, GSK's ROE is +0.30%, compared to SRXH's ROE of +4.36%. Regarding short-term risk, GSK is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check SRXH's competition here
GSK vs SCLXW Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, SCLXW has a market cap of 1.4M. Regarding current trading prices, GSK is priced at $59.46, while SCLXW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas SCLXW's P/E ratio is N/A. In terms of profitability, GSK's ROE is +0.30%, compared to SCLXW's ROE of +1.81%. Regarding short-term risk, GSK is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check SCLXW's competition here
GSK vs BDSIW Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, GSK is priced at $59.46, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas BDSIW's P/E ratio is N/A. In terms of profitability, GSK's ROE is +0.30%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, GSK is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check BDSIW's competition here
GSK vs CRXT Comparison February 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 120.1B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, GSK is priced at $59.46, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 15.75, whereas CRXT's P/E ratio is -0.02. In terms of profitability, GSK's ROE is +0.30%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, GSK is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check CRXT's competition here